Patiromer to Enable Spironolactone Use in the Treatment of Patients with Resistant Hypertension and Chronic Kidney Disease: Rationale and Design of the AMBER Study. (2018)
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1159/000492622
PubMed Identifier: 30176673
Publication URI: http://europepmc.org/abstract/MED/30176673
Type: Journal Article/Review
Volume: 48
Parent Publication: American journal of nephrology
Issue: 3
ISSN: 0250-8095